The investor presentation “MagSense® Technology: Early Detection of Cancer Through Targeted Imaging” has been announced and is available for download here.
Download the non-deal roadshow presentation MagSense Technology.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)